ArticleJournal of biosciences2025
Pharmaceutical adoption of microphysiological systems in India is contingent on their economics among other aspects.
Article in Journal of biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microphysiological systems (MPS) have enabled a paradigm shift from reliance on animals to human-relevant tools for drug development. Following progressive regulations by USA, Europe, Canada, and other nations, India authorized the use of MPS in its New Drugs and Clinical Trials Rules (Amendment) 2023. However, while the use of these models by the pharmaceutical industry has been documented globally, this information is sorely lacking among developing nations such as India. We uncovered that embracing MPS in the Indian community is challenged by multiple factors. To actively participate in the global shift toward human-centric biomedical research, India must enhance its MPS awareness, skill development, regulatory guidelines, local resource availability, and return on investments. We found that there is a significant diversity in the costs of different MPS in India and provide recommendations to manage their expenses in the context of low-income nations. In conclusion, our findings will hasten MPS adoption, limit archaic animal use, help in formulation of institute policies, and shape the country's investment in contemporary science.
Indexed as
Identifiers
40501090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.